NCT02300844 is a Phase 1 clinical trial of NNC0174-0833 in Metabolism and Nutrition Disorder, sponsored by Novo Nordisk A/S.

Who is sponsoring NCT02300844?

NCT02300844 is sponsored by Novo Nordisk A/S.

What drugs are being tested in NCT02300844?

Interventions in NCT02300844: NNC0174-0833, placebo.

What condition does NCT02300844 study?

NCT02300844 studies Metabolism and Nutrition Disorder, Obesity.

Is NCT02300844 still recruiting?

NCT02300844 is currently completed. Last updated 24 January 2018.

Last reviewed 2018-01-24 · How we verify

NCT02300844

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male Subjects

Completed Phase 1 Last updated 24 January 2018

What this trial tests

Phase 1 trial testing NNC0174-0833 in Metabolism and Nutrition Disorder in 54 participants. Completed in 21 March 2016.

Timeline

1 December 2014

Primary endpoint
21 March 2016

21 March 2016

Quick facts

Lead sponsor	Novo Nordisk A/S
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	54
Start date	1 December 2014
Primary completion	21 March 2016
Estimated completion	21 March 2016
Sites	1 location across United States

Drugs / interventions tested

NNC0174-0833 — full drug profile →
placebo

Conditions studied

Metabolism and Nutrition Disorder — all drugs for Metabolism and Nutrition Disorder →
Obesity — all drugs for Obesity →

Sponsor

Novo Nordisk A/S — full company profile →

Who can join

Adults 22 to 64, male only, with Metabolism and Nutrition Disorder or Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial is conducted in the United States of America (USA). The aim of this trial is to investigate the safety, tolerability and pharmacokinetics of single doses of NNC0174-0833 in normal weight, overweight to obese but otherwise healthy male subjects.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Comprehensive Review of Current and Upcoming Anti-Obesity Drugs.
Son JW, Kim S. · · 2020 · cited 92× · PMID 33389955 · DOI 10.4093/dmj.2020.0258
Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy.
Angelidi AM, Belanger MJ, Kokkinos A, Koliaki CC, et al · · 2022 · cited 83× · PMID 35552683 · DOI 10.1210/endrev/bnab034

Verify or expand the search:

Other trials of NNC0174-0833

Trials testing the same drug.

NCT04209049 — A Research Study Looking Into Blood Levels of NNC0174-0833 in People With Normal and Impaired Kidney Function · Phase 1 · completed
NCT04074174 — Research Study to Investigate the Effect of NNC0174-0833 on a Birth Control Pill in Women Who Are Not Able to Become Pre · Phase 1 · completed
NCT03856047 — Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity. · Phase 2 · completed
NCT03787225 — A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or W · Phase 1 · completed
NCT03600480 — A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese · Phase 1 · completed

Other recruiting trials for Metabolism and Nutrition Disorder

Currently open trials in the same condition.

NCT05785221 — Energy Metabolism Profiles Over Weight-loss and Eating Responses · NA · active not recruiting
NCT03669809 — The Biological Rhythm of Human Metabolite · recruiting

Other Novo Nordisk A/S trials

Trials by the same sponsor.

NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · not yet recruiting
NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles · Phase 3 · not yet recruiting
NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight · Phase 3 · not yet recruiting
NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe · Phase 3 · not yet recruiting
NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02300844 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
Last refreshed: 24 January 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02300844.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing